 |
|
Fluphenazine vs Placebo Supplementation for Prodromal Signs of Relapse in Schizophrenia
Stephen R. Marder, MD;
William C. Wirshing, MD;
Theodore Van Putten, MD;
Jim Mintz, PhD;
Joanne McKenzie, RN;
Kathleen Johnston-Cronk, MS;
Malca Lebell, PhD;
Robert P. Liberman, MD
Arch Gen Psychiatry. 1994;51(4):280-287.
Abstract
| |
Background
We studied the effectiveness of treating patients with low doses of fluphenazine decanoate and supplementing them with oral fluphenazine when there was evidence of prodromal symptoms of psychotic exacerbations.
Methods
Eighty schizophrenic patients who were receiving 5 to 10 mg of fluphenazine decanoate every 2 weeks were monitored for prodromal symptoms using an idiosyncratic prodromal rating scale. When patients met our criteria for a prodromal episode, they were randomly assigned to a double-blind comparison of oral fluphenazine hydrochloride (5 mg twice daily) or a placebo for the current and future prodromal episodes. We compared rates of psychotic exacerbations in the two treatment groups.
Results
Thirty-six patients (45%) met the criteria for a prodrome at some point during the trial and were randomized to drug or placebo. Using survival analysis during the entire 2 years, we did not find a significant difference between fluphenazine and placebo in the likelihood that a prodrome would continue to an exacerbation. Survival analysis beginning at the start of the second year of treatment did indicate a significant reduction in exacerbation risk for patients receiving drug supplementation (P=.032). Similarly, there was no difference between the two groups in the proportion of time at risk spent in exacerbation during the first year, but patients receiving active drug supplementation spent less time in an exacerbated state in the second year (P=.05).
Conclusions
Our treatment strategy appeared to be effective for some patients, particularly those who were able to remain in the study beyond the first year. Although the occurrence of a prodrome was a fairly good marker that a patient was at high risk of ultimate exacerbation with our low-dose maintenance protocol, prodromes were not highly sensitive indicators of imminent exacerbation.
Author Affiliations
From the West Los Angeles (Calif) Veterans Affairs Medical Center, Brentwood Division (Drs Marder, Wirshing, Van Putten, Mintz, Lebell, and Liberman, and Ms McKenzie), and the Department of Psychiatry and Biobehavioral Sciences, UCLA, Los Angeles, Calif (Drs Marder, Wirshing, Van Putten, Mintz, and Liberman and Ms Johnston-Cronk).  Deceased.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Clinical Outcome Following Neuroleptic Discontinuation in Patients With Remitted Recent-Onset Schizophrenia
Gitlin et al.
Focus 2004;2:122-130.
ABSTRACT
| FULL TEXT
Monitoring and Care of Young People at Incipient Risk of Psychosis
Yung et al.
Focus 2004;2:158-174.
ABSTRACT
| FULL TEXT
Clinical Outcome Following Neuroleptic Discontinuation in Patients With Remitted Recent-Onset Schizophrenia
Gitlin et al.
Am. J. Psychiatry 2001;158:1835-1842.
ABSTRACT
| FULL TEXT
Psychopharmacologic Treatment Strategies for Depression, Bipolar Disorder, and Schizophrenia
Glick et al.
ANN INTERN MED 2001;134:47-60.
ABSTRACT
| FULL TEXT
Schizophrenia: early warning signs
Birchwood et al.
Adv. Psychiatr. Treat. 2000;6:93-101.
FULL TEXT
A Program for Relapse Prevention in Schizophrenia: A Controlled Study
Herz et al.
Arch Gen Psychiatry 2000;57:277-283.
ABSTRACT
| FULL TEXT
The Early Course of Schizophrenia and Long-term Maintenance Neuroleptic Therapy
Nuechterlein et al.
Arch Gen Psychiatry 1995;52:203-205.
ABSTRACT
Autonomic Abnormalities in Schizophrenia: State or Trait Indicators?
Dawson et al.
Arch Gen Psychiatry 1994;51:813-824.
ABSTRACT
|
